PROCEPT Biorobotics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by PROCEPT Biorobotics Corporation on October 21, 2021. The filing reports a corporate governance event: the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: Elisabeth Sandoval was appointed as a Class I director, effective immediately on October 21, 2021.
- Term: Ms. Sandoval's term expires at the 2022 Annual Meeting of Stockholders.
Compensation and Management Commentary
Ms. Sandoval will receive standard non-employee director compensation under the Company's Director Compensation Program. This includes an initial restricted stock unit (RSU) award valued at $200,000. The vesting schedule is as follows:
- One-third (1/3) vests on the first anniversary of her appointment.
- The remaining two-thirds (2/3) vest on each annual anniversary during the subsequent two-year period, subject to continued service.
The Company also entered into a standard indemnification agreement with Ms. Sandoval. No other transactions or arrangements requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the full text of the Director Compensation Program to confirm standard compensation rates for other directors.
- Review the attached Press Release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the vesting conditions and potential forfeiture clauses in the RSU grant agreement.
- Check subsequent filings for the impact of the new director on Board committee assignments.